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PEXPEDITED REVIEWS
Initial Worldwide Experience With the
WATCHMAN Left Atrial Appendage System
for Stroke Prevention in Atrial Fibrillation
Peter B. Sick, MD,* Gerhard Schuler, MD,† Karl Eugen Hauptmann, MD,‡
Eberhard Grube, MD, FACC,§ Steve Yakubov, MD, FACC, Zoltan G. Turi, MD, FACC,¶
Gregory Mishkel, MD, FACC,# Steve Almany, MD, FACC,** David R. Holmes, MD, FACC††
Regensburg, Leipzig, Trier, and Siegburg, Germany; Columbus, Ohio; Camden, New Jersey;
Springfield, Illinois; Royal Oak, Michigan; and Rochester, Minnesota
Objectives This study assessed the feasibility of implanting a device in the left atrial appendage (LAA) in patients with atrial
fibrillation (AF) to prevent thromboembolic stroke.
Background Meta-analyses confirmed that in cases of left atrial thrombus in nonrheumatic AF patients approximately 90% of
them are in the LAA.
Methods The WATCHMAN Left Atrial Appendage System (Atritech Inc., Plymouth, Minnesota) is a nitinol device implanted
percutaneously to seal the LAA. Patients were followed by clinical and transesophageal echocardiography at 45
days and 6 months with annual clinical follow-up thereafter.
Results Sixty-six patients underwent device implantation. Mean follow-up was 740  341 days. At 45 days, 93% (54 of
58) devices showed successful sealing of LAA according to protocol. Two patients experienced device emboliza-
tion, both successfully retrieved percutaneously. No embolizations occurred in 53 patients enrolled after modifi-
cation of fixation barbs. There were 2 cardiac tamponades, 1 air embolism, and 1 delivery wire fracture (first
generation) with surgical explantation but no long-term sequelae for the patient. Four patients developed a flat
thrombus layer on the device at 6 months that resolved with additional anticoagulation. Two patients experi-
enced transient ischemic attack, 1 without visible thrombus. There were 2 deaths, neither device related. Au-
topsy documented a stable, fully endothelialized device 9 months after implantation. No strokes occurred during
follow-up despite 90% of patients with discontinuation of anticoagulation.
Conclusions Preliminary data suggest LAA occlusion with the WATCHMAN System to be safe and feasible. A randomized
study is ongoing comparing oral anticoagulation with percutaneous closure. (J Am Coll Cardiol 2007;49:
1490–5) © 2007 by the American College of Cardiology Foundation










wtrial fibrillation (AF) is the most common cardiac abnor-
ality associated with ischemic stroke. Among patients
ith AF, there is an approximate 5% annual stroke risk, a
-fold increase over an age-matched population in sinus
hythm. Increased stroke risk correlates with age, previous
ransitory ischemic attack (TIA) or stroke, hypertension,
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007, accepted February 28, 2007.iabetes, impaired left ventricular function, and a large left
trium. Most ischemic strokes associated with AF are
hought to be secondary to embolization from the left atrial
ppendage (LAA). Transesophageal echocardiography
TEE) data show left atrial thrombi to be more frequent in
F patients with ischemic stroke as compared with AF
atients without stroke (1).
See page 1496
There is a wealth of published literature from controlled
rials on stroke prevention in AF demonstrating the effec-
iveness of anticoagulation (2–5). The SPAF (Stroke Pre-
ention in Atrial Fibrillation)-III studies confirmed that
arfarin adjusted for a target international normalized ratio
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April 3, 2007:1490–5 WATCHMAN LAA for AFs affected by a large number of drug, dietary, and metabolic
nteractions, it can be unpredictable in some patients and
ifficult to manage. The narrow therapeutic window, need
or frequent blood drawing for monitoring, potentially
ethal complications, and poor patient tolerance have re-
ulted in a majority of patients with AF not receiving
herapeutic anticoagulation, in particular older patients who
re at increased risk of stroke. Aspirin, although generally
etter tolerated, is clearly less effective at stroke prevention
6).
Given the problems with the available pharmacologic
pproaches, a device-based solution has been sought to
rovide protection against thromboembolic events in pa-
ients with AF. The purpose of this study was to assess the
afety and feasibility of deploying the WATCHMAN Left
trial Appendage Occlusion Device (Atritech Inc., Ply-
outh, Minnesota) in a pilot trial.
ethods
tudy design and inclusion/exclusion criteria. This was
n open-label nonrandomized pilot study designed to dem-
nstrate the safety and feasibility of the new WATCH-
AN Left Atrial Appendage Occlusion Device. Adult
atients over 18 years of age with a life expectancy of at least
years, documented chronic or paroxysmal nonvalvular AF
ho were eligible for warfarin therapy were screened as
andidates for the WATCHMAN investigation. Patients
ad to have a minimum CHADS2 score of at least 1. The
HADS2 score is an overall risk assessment for stroke based
n a scale of 0 to 6. To calculate a patient’s score, 1 point is
ssigned for the presence of congestive heart failure, diabe-
es, history of hypertension, or age 75 years. Two points
re assigned for prior stroke or TIA. The score can be used
o approximate the annual risk of stroke (6). If patients had
rior embolic stroke, full recovery without significant neu-
ologic residual deficits had to be documented.
Patients with any congenital heart disease including atrial
eptal defect or septal aneurysms, symptomatic carotid
isease, symptomatic valvular disease, aortic arch atheroma,
r presence of a prosthetic valve were excluded. Other
xclusion criteria included intracardiac thrombus, including
AA or spontaneous echo contrast visualized by TEE
ithin 48 h before planned WATCHMAN implant. Left
entricular ejection fraction below 35% measured by trans-
horacic echocardiography, more than 1 pacemaker lead or
n implanted cardioverter-defibrillator, hypercoagulable
tate, or pregnancy were also criteria for exclusion.
evice implantation. The WATCHMAN Left Atrial
ppendage System is a 3-part system consisting of a
rans-septal access sheath, a delivery catheter, and an im-
lantable nitinol device. The system is designed to facilitate
evice placement via femoral venous access via the trans-
eptal route into the LAA. The WATCHMAN implant
omprises a self-expanding nitinol frame structure with
xation barbs and a permeable polyester fabric that covershe atrial facing surface of the
evice. The device is constrained
ithin a delivery catheter until
eployment into the LAA. The
ATCHMAN implant (Fig. 1)
s available in diameters of 21,
4, 27, 30, and 33 mm to accom-
odate the unique anatomy of
ach patient’s LAA. Device size
as chosen to be 10% to 20%
arger than diameter of the LAA
ody to have sufficient compression for stable positioning of
he device. A revised model of the device was introduced
fter the initial 16 patients with a reinforced delivery cable
nd a series of barbs to facilitate device attachment and
revent embolization.
The 14-F trans-septal access sheath is available in a
ouble- and single-curve configuration (Fig. 2). The access
heath is utilized to gain access to the LAA and serves as a
onduit for the delivery catheter. The WATCHMAN
mplant is deployed by retracting the sheath covering the
evice. The implant can be partially recaptured and rede-
loyed if the implant location is deemed unsatisfactory or
ecaptured completely if a different sized device is deter-
ined to be more suitable.
The implantation procedure was performed under TEE
uidance. After trans-septal puncture and catheter place-
ent into the LAA and LAA angiography was performed,
n optimal device size based on LAA measurements was
elected. Proper device position was confirmed by angiog-
aphy and echocardiography (Fig. 3). Patients were typically
ospitalized overnight and discharged the next day. At 45
ays after implantation, repeat TEE was performed and
epeated at 6-month follow-up. Annual patient follow-up
Figure 1 WATCHMAN Implant
WATCHMAN device, nitinol cage with a polytetrafluoroethylene
membrane on the surface, and fixation barbs around the perimeter
Abbreviations
and Acronyms
AF  atrial fibrillation




































































1492 Sick et al. JACC Vol. 49, No. 13, 2007
WATCHMAN LAA for AF April 3, 2007:1490–5isits up to 5 years are planned with TEE only in case of
linical necessity.
edical treatment. During implantation, heparin was
iven to achieve an activated clotting time of at least 250 s
mmediately after the trans-septal puncture to keep antico-
gulation throughout the whole implantation procedure.
fter implantation intravenous heparin was stopped and
eplaced by low molecular weight heparin until an interna-
ional normalized ratio of 2 was achieved with warfarin.
atients were discharged from hospital on aspirin 81 to 100
g daily and warfarin for at least 45 days, with dosage of the
atter adjusted to keep the international normalized ratio
etween 2 and 3. If echocardiographic criteria for successful
ealing of the LAA (as mentioned in the following section)
ere fulfilled at 45 days, warfarin therapy was discontinued
hile aspirin was continued indefinitely.
nd points. PRIMARY PERFORMANCE END POINT: DEVICE
OSITION AT 45 DAYS AFTER PLACEMENT. The primary end
oint for this study was successful device implantation and
uccessful sealing of the LAA as measured by TEE at 45
ays after implant without major adverse events. The rate of
uccessful placement was calculated as the percentage of
atients with the device appropriately positioned, the LAA
ompletely sealed with absence of flow or with minimal flow
round the device (jet of 3 mm) as measured by TEE at
5 days after placement (Fig. 3).
ajor adverse events. Major adverse events were defined
s death, stroke, systemic embolism, and major bleeding
equiring invasive treatment or blood transfusion. Adverse
Figure 2 Introduction Sheath With Double and
Single Curve for Different Anatomical Situations
Introducer sheaths with different shapesvent data were analyzed as the number of adverse events inhe patients’ cumulative follow-up time (in patient-
onths), for each version of the device.
tatistical analysis. Estimates for frequency of occurrence
f events are expressed as percentages or rates. Continuous
ariables are summarized by mean, standard deviation, and
inimum and maximum values.
thics. Written informed consent was obtained from each
ndividual, and the procedures were performed in accor-
ance with the ethical standards of each participating
nstitution and with the Helsinki Declaration of 1975,
evised in 1983.
esults
aseline characteristics. There were 75 patients in 3
ardiology centers in Europe and 4 centers in the U.S.
ho met all inclusion and exclusion criteria and were
nrolled in the study. Mean patient age was 68.5 years
range 47.4 to 83.2 years), 64% were men. Of the 75
atients with attempted device placement, 66 had suc-
essful implantation (88%). In the remaining 9 patients,
he trans-septal sheath could not be placed in the LAA
ue to a scar in the right groin in 1 and a core wire
alfunction in 1 patient, while 7 had LAA anatomy that
as unsuitable for device placement. The average
HADS2 score of the 66 patients with implants was 1.8
1.1 (range 0 to 5), indicating a moderate level of risk
or stroke. The most frequently occurring CHADS2
haracteristic was hypertension (55 of 66 [83.3%]) fol-
owed by diabetes (22 of 66 [33.3%]).
The average LAA diameter was 19.6 mm, and median
mplant size was 24 mm. Nine patients received a 21-mm,
1 received a 24-mm, 17 received a 27-mm, and 8 received
30-mm WATCHMAN device. A mean of 1  1.6
evices per patient (range 1 to 4) were required until optimal
Figure 3 Six-Month TEE Control With a
Well-Positioned WATCHMAN Device in the LAA
Little color flow is seen behind the device, and no flow around the margins.
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April 3, 2007:1490–5 WATCHMAN LAA for AFAA closure was obtained. Fifty-eight patients came for
5-day follow-up, 5 patients came for later follow-up, so
urrently 3 patients are definitely lost to follow-up. Ninety-
hree percent (54 of 58) of the devices satisfied the primary
fficacy end point with complete closure of the LAA or
ithout significant flow around the device. Mean follow-up
as 24  11 months. Thirteen patients have been followed
or more than 4 years, 20 for more than 3 years, and 29 for
ore than 2 years after implantation.
dverse events. A number of complications were associ-
ted especially with the first-generation device (Table 1).
hree patients experienced device failure, 2 of which were
mbolizations, and 1 was a delivery system failure (fractured
elivery wire). The 2 embolized devices were both retrieved
ercutaneously; 1 of these patients suffered from internal
leeding, but was discharged without negative conse-
uences. One of the broken delivery wires of the first-
eneration devices did not result in clinically relevant
equelae for the patient: the device was implanted correctly
nd the broken delivery wire could be removed. Another
atient, however, required surgical device explantation after
ncorrect positioning of the device without the possibility of
orrecting the position due to the broken wire. After
odification of the delivery system in the second-
eneration devices, this was no longer an issue. In another
atient, air embolism led to a malignant arrhythmia requir-
ng cardiopulmonary resuscitation. The patient was dis-
harged from hospital without any adverse consequences; a
ummary of Adverse Eventsring and After Implanta ion








Implant failure due to anatomical
reasons of LAA, scar in the
groin
2 6
Air embolism without device
implantation
1 0
Successful implantations 13 53
Stroke 0 0
Death, not device related 2 0
Core wire failure with surgical
device explantation
1 0
Core wire failure without
consequences
1 0
Device embolization 2 0
Internal bleeding due to retrieval
after device embolization
1 0
Pericardial effusion/tamponade 1 1
Minor pericardial effusion without
treatment
0 3
Thrombus on device (noted after
6 and 12 months)
0 4




Femoral pseudoaneurysm 1 1
AA  left atrial appendage; TIA  transient ischemic attack.evice, however, was not implanted. After the initial 16atients, the device was redesigned. The remaining 53
atients underwent implantation with the second-
eneration device; no further embolizations occurred. Peri-
ardial effusions occurred in 2 of the 75 cases (2.6%) related
o the trans-septal puncture procedure. One pericardial
ffusion appeared related to an overly vigorous “tug test”
sually performed for proof of stability of the device in the
AA. Because the LAA is quite thin, the technique was
odified to observe the LAA during the tug, either by
njecting contrast into the LAA to visualize the chamber, or
ith continuous TEE observation. No further tug-related
ffusions were observed.
During follow-up, there were no major strokes at all.
ix patients were not followed at 6 months, 2 of them
ere the patients with device embolizations mentioned in
he preceding text, and 4 of them missed follow-up but
ere seen later in the course of the study; all of them were
ff coumadin. So there were 60 patients at 6 months
ollow-up, and 91.7% (55 of 60) of patients had discon-
inued warfarin therapy. No ischemic stroke or systemic
mbolisms have occurred during a mean follow-up of 24
onths. One patient with a history of TIA experienced a
IA at 4 months without thrombus visible on the device;
nother patient had a TIA at 6 months with a smooth
ayer of thrombus detected on the surface of the device
Fig. 4). There were 3 additional patients showing
hrombus formation on the atrial surface of the device
ithout neurological symptoms. One of these patients
as noncompliant with anticoagulation treatment start-
ng early after device implantation. After an additional 6
onths of warfarin therapy, all thrombi had resolved, and
atients were maintained on aspirin alone. There were 3
Figure 4 Layered Thrombus Formation on
the Device 6 Months After Implantation
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WATCHMAN LAA for AF April 3, 2007:1490–5ajor bleeding complications, 2 of which were pericardial
ffusions treated percutaneously, and 1 internal bleed due
o retrieval after device embolization; additionally there
ere 2 minor bleedings with hematomas in the groin
equiring transfusion.
One patient died after 9 months due to an ascending
ortic dissection. Autopsy documented a stable, well-
Figure 5 Anatomical View of the WATCHMAN Device in the
LAA in a Patient Who Died From Aortic Dissection
This patient died 9 months after implantation. Stable position and endotheliali-
zation of the device were confirmed. LAA  left atrial appendage. Reproduced
with permission from K. E. Hauptmann, Trier, Germany.Figure 6 Flow Chart of the Trial With Number of Implants and Attemndothelialized device with complete LAA occlusion
Fig. 5). One additional patient died of causes unrelated
o the device; this patient had multiorgan failure after
owel surgery. Figure 6 illustrates implantation failures
nd drop outs during follow-up for the 2 generations of
he device.
iscussion
ore than 15% of cerebral ischemia is due to AF (7–9).
nticoagulation therapy is the method of choice for
revention of thromboembolic events in AF; however,
nly a low number of all patients with indication for
nticoagulation are currently under treatment (10,11). It
s well known in AF that if thrombi are found in the left
trium more than 90% are in the LAA (12–14). The
ATCHMAN Left Atrial Appendage Device was de-
eloped as a mechanical barrier to avoid embolization
rom the LAA by sealing the orifice of the LAA.
This study demonstrated that implantation of the
ATCHMAN device is a generally safe and feasible
ethod for percutaneously sealing the LAA. Modifica-
ion of the delivery system and the WATCHMAN
mplant resulted in marked reduction of complications
ssociated with device delivery. Pericardial effusions ap-
eared related to transseptal or tug techniques, both of
hich are expected to decline with operator experience
nd adoption of technique modifications as discussed in
he previous text.
The expected annual risk of stroke based on the
HADS2 score in this study cohort was calculated to be
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April 3, 2007:1490–5 WATCHMAN LAA for AFhe patients in this trial despite discontinuation of
nticoagulation in 90% and an average follow-up of 2
ears. Although the number of patients does not provide
ufficient power to demonstrate equivalence or superiority
o anticoagulation, the results appear generally compara-
le to those reported for the PLAATO System (ev3 Inc.,
lymouth, Minnesota), which has also been demon-
trated in 205 of 210 implanted patients to have a lower
vent rate of stroke (5 strokes at a mean follow-up of 14.7
onths) compared with the expected stroke rate pre-
icted by the CHADS2 score (15,16). Four patients did
ave thrombus seen on the device at follow-up, including
of the 2 patients who had a TIA. Given the known
ccurrence of spontaneous thrombus formation in AF
atients despite therapeutic anticoagulation (17), this
nding may not be surprising. The endothelialization
rocess may not be finished at 45 days after implantation
hen warfarin is discontinued, so we have modified our
herapeutic regimen to include concomitant therapy with
spirin and clopidogrel between 45 days and the 6-month
ollow-up. Complete endothelialization was documented
t 9 months in the patient who died due to an aortic
neurysm (Fig. 5).
tudy limitations. This study was a feasibility trial primar-
ly designed to test the safety of the implantation procedure.
he use of a first-generation device and incorporation of
perator learning curves potentially biased the early results.
he study size was not intended to be of sufficient power to
ddress efficacy.
onclusions
n conclusion, LAA occlusion with the WATCHMAN
evice appears to be safe with preliminary results consistent
ith low stroke risk despite discontinuation of anticoagula-
ion. Because of the growing prevalence of AF in the elderly
nd others, in whom anticoagulation carries a high risk or is
ontraindicated, these devices may offer an attractive solu-
ion to the AF-related emboli problem. A randomized trial
ommenced in February 2005 comparing anticoagulation
herapy with WATCHMAN implantation to assess if
ercutaneous LAA occlusion is an alternative treatment
trategy to long-term anticoagulation.
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